Murphy Timothy P, Cooper Christopher J, Matsumoto Alan H, Cutlip Donald E, Pencina Karol M, Jamerson Kenneth, Tuttle Katherine R, Shapiro Joseph I, D'Agostino Ralph, Massaro Joseph, Henrich William, Dworkin Lance D
Rhode Island Hospital, Providence, Rhode Island; Alpert Medical School of Brown University, Providence, Rhode Island.
University of Toledo, Toledo, Ohio.
J Am Coll Cardiol. 2015 Dec 8;66(22):2487-94. doi: 10.1016/j.jacc.2015.09.073.
Multiple randomized clinical trials comparing renal artery stent placement plus medical therapy with medical therapy alone have not shown any benefit of stent placement. However, debate continues whether patients with extreme pressure gradients, stenosis severity, or baseline blood pressure benefit from stent revascularization.
The study sought to test the hypothesis that pressure gradients, stenosis severity, and/or baseline blood pressure affects outcomes after renal artery stent placement.
Using data from 947 patients with a history of hypertension or chronic kidney disease from the largest randomized trial of renal artery stent placement, the CORAL (Cardiovascular Outcomes in Renal Atherosclerotic Lesions) study, we performed exploratory analyses to determine if subsets of patients experienced better outcomes after stent placement than the overall cohort. We examined baseline stenosis severity, systolic blood pressure, and translesion pressure gradient (peak systolic and mean) and performed interaction tests and Cox proportional hazards analyses for the occurrence of the primary endpoint through all follow-up, to examine the effect of these variables on outcomes by treatment group.
There were no statistically significant differences in outcomes based on the examined variables nor were there any consistent nonsignificant trends.
Based on data from the CORAL randomized trial, there is no evidence of a significant treatment effect of the renal artery stent procedure compared with medical therapy alone based on stenosis severity, level of systolic blood pressure elevation, or according to the magnitude of the trans-stenotic pressure gradient. (Benefits of Medical Therapy Plus Stenting for Renal Atherosclerotic Lesions [CORAL]; NCT00081731).
多项比较肾动脉支架置入术联合药物治疗与单纯药物治疗的随机临床试验未显示支架置入有任何益处。然而,对于压力梯度极高、狭窄严重程度或基线血压的患者是否能从支架血管重建术中获益,仍存在争议。
本研究旨在检验压力梯度、狭窄严重程度和/或基线血压是否会影响肾动脉支架置入术后的预后这一假设。
利用肾动脉支架置入最大规模随机试验“CORAL(肾动脉粥样硬化病变的心血管结局)研究”中947例有高血压或慢性肾病病史患者的数据,我们进行了探索性分析,以确定支架置入术后患者亚组的预后是否优于整个队列。我们检查了基线狭窄严重程度、收缩压和跨病变压力梯度(收缩压峰值和平均值),并通过所有随访对主要终点事件的发生进行交互检验和Cox比例风险分析,以按治疗组检验这些变量对预后的影响。
基于所检查的变量,预后无统计学显著差异,也没有任何一致的非显著趋势。
基于CORAL随机试验的数据,根据狭窄严重程度、收缩压升高水平或跨狭窄压力梯度大小,没有证据表明肾动脉支架手术与单纯药物治疗相比有显著治疗效果。(肾动脉粥样硬化病变的药物治疗加支架置入的益处[CORAL];NCT00081731)